Marksans Pharma Limited (NSE:MARKSANS)
India · Delayed Price · Currency is INR 233.50
-5.64 (-2.36%)
Jun 5, 2026, 3:30 PM IST
Marksans Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 4,179 | 3,806 | 3,137 | 2,663 | 1,868 |
Depreciation & Amortization | 986.32 | 830.02 | 740.55 | 518.53 | 447.76 |
Other Amortization | - | 3.84 | 2.15 | - | - |
Loss (Gain) From Sale of Assets | 0.64 | 0.33 | -0.94 | 2.64 | - |
Loss (Gain) From Sale of Investments | 16.98 | 33.12 | -43.63 | 108.02 | -56.23 |
Stock-Based Compensation | 33.38 | - | - | - | - |
Provision & Write-off of Bad Debts | 218.58 | 83.28 | 51.57 | 143.61 | 26.32 |
Other Operating Activities | -229.08 | -281.96 | -320.71 | 52.89 | -186.4 |
Change in Accounts Receivable | -313.9 | -777.9 | -371.67 | -275.18 | -1,039 |
Change in Inventory | -387.25 | -1,955 | -1,127 | -448.5 | -178.49 |
Change in Accounts Payable | - | - | - | - | 284.79 |
Change in Other Net Operating Assets | 76.58 | 324.83 | 236.48 | -390.97 | -173.98 |
Operating Cash Flow | 4,581 | 2,067 | 2,304 | 2,374 | 992.57 |
Operating Cash Flow Growth | 121.68% | -10.30% | -2.95% | 139.19% | -44.42% |
Capital Expenditures | -1,305 | -1,729 | -2,088 | -536.31 | -463.3 |
Sale of Property, Plant & Equipment | 9.77 | 12.49 | 8.54 | 3.77 | 0.34 |
Cash Acquisitions | - | - | - | -266.1 | - |
Investment in Securities | -1,450 | 269.87 | -259.48 | -1 | -428.55 |
Other Investing Activities | 262.47 | 956.74 | 930.92 | -1,792 | 47.6 |
Investing Cash Flow | -2,483 | -490.09 | -1,408 | -2,592 | -843.91 |
Short-Term Debt Issued | 65.06 | - | - | 52.96 | 225.52 |
Total Debt Issued | 65.06 | - | - | 52.96 | 225.52 |
Short-Term Debt Repaid | - | -60.06 | -124.97 | - | - |
Long-Term Debt Repaid | -383.96 | -295.65 | -284 | -207.73 | -155.17 |
Total Debt Repaid | -383.96 | -355.71 | -408.97 | -207.73 | -155.17 |
Net Debt Issued (Repaid) | -318.9 | -355.71 | -408.97 | -154.77 | 70.35 |
Repurchase of Common Stock | - | - | - | -321.14 | - |
Common Dividends Paid | -362.53 | -271.9 | -226.58 | -101.71 | -105.83 |
Dividends Paid | -362.53 | -271.9 | -226.58 | -101.71 | -105.83 |
Other Financing Activities | -27.85 | -23.85 | -51.72 | 2,606 | 830.59 |
Financing Cash Flow | -709.28 | -651.46 | -687.27 | 1,978 | 795.11 |
Foreign Exchange Rate Adjustments | -5.79 | - | - | 0.02 | - |
Net Cash Flow | 1,384 | 925.09 | 208.4 | 1,760 | 943.77 |
Free Cash Flow | 3,276 | 337.45 | 215.69 | 1,838 | 529.27 |
Free Cash Flow Growth | 870.81% | 56.45% | -88.26% | 247.24% | -59.95% |
Free Cash Flow Margin | 11.10% | 1.29% | 0.99% | 9.92% | 3.55% |
Free Cash Flow Per Share | 7.23 | 0.74 | 0.48 | 4.42 | 1.29 |
Cash Interest Paid | 27.85 | 23.85 | 51.72 | 60.66 | 80.96 |
Cash Income Tax Paid | 1,397 | 1,259 | 1,223 | 630.14 | 728.59 |
Levered Free Cash Flow | 703.47 | -725.4 | -510.23 | 661.16 | -227.75 |
Unlevered Free Cash Flow | 854.25 | -652.53 | -440.21 | 699.26 | -191.87 |
Change in Working Capital | -624.57 | -2,408 | -1,262 | -1,115 | -1,107 |